Pharmasset, Inc.

Other

Emory University

University of Georgia Research Foundation, Inc.

Michael J Otto

Junxing Shi

Kyoichi A Watanabe

Lieven Stuyver

Raymond F Schinazi

Chung K Chu

Yongseok Choi

Giuseppe Gumina

Youhoon Chong

The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2',3&#x2032;-dideoxy-5-fluorocytidine or N.sup.4-acyl-2&#x2032;,3&#x2032;-didehyd-ro-2&#x2032;,3&#x2032;-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

[object Object]

A process for assessing mitochondrial toxicity of a compound that includes contacting nucleic acids from a host with an amplification reaction mixture that contains at least two primers that provide detectable signals, wherein:

Simultaneous quantification of nucleic acids in diseased cells

The present invention is directed to a compound, method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N-acylcytosine-1,3-dioxolane and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections

Processes and methods for the simultaneous quantification of nucleic acids in diseased cells that are based on real-time PCR are provided. The real-time PCR protocol is an excellent tool for reliable quantification of in vitro drug screening and evaluation protocols to determine the efficacy of potential anti-viral agents. Quantification using these simultaneous PCR cycle threshold (Ct) detection techniques during one-step real-time RT-PCR (Applied Biosystems, CA) eliminates the variability resulting from quantification of end-point RT-PCR products. In addition, the mitochondrial toxicity assay is an added tool to assess potential side-effects for these chemotherapeutic agents.

Kit for assessing mitochondrial toxicity

The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N-acyl-2',3&#x2032;-dideoxy-5-fluorocytidine or N-acyl-2&#x2032;,3&#x2032;-didehydro-2&#x2032;,3&#x2032;-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

The present invention includes compounds and compositions of &#x3b2;-halonucleosides, as well as methods to treat HIV, HBV or abnormal cellular proliferation comprising administering said compounds or compositions.

Growing community of inventors

Lilburn, GA, United States of America

Michael J Otto